Abstract
Identifying the pathogenic variant in a rare disease (RD) patient is the first step in ending their diagnostic odyssey. De novo (Dn) variants affecting protein-coding DNA are a well-established cause of Mendelian disorders in RD patients. Constrained coding regions (CCRs) are specific segments of coding DNA which are devoid of functional variants in healthy individuals. Furthermore, the most constrained regions, those in percentile bin >95 (CCR95), are significantly enriched for functional pathogenic variants and could therefore be useful for clinical variant prioritisation.
We aimed to evaluate the diagnostic utility of incorporating Dn, CCR95 and Dn_CCR95 status into the variant prioritisation cascade for RD patients that have undergone genomic sequencing. Using data from the Genomics England 100,000 Genomes Project v12, we selected 3,090 trios that have undergone diagnostic evaluation and been analysed with an advanced Dn identification pipeline. For this analysis we have excluded all non-autosomal variants.
Our analysis shows the diagnostic rate increased from 71% in the full cohort to 81% when evaluating just the CCR95 variants, 84% for Dn variants and 87% for Dn_CCR variants. Of note, manual evaluation of the Dn_CCR95 variants from the undiagnosed patients revealed a putative diagnosis in 64% of patients (25 of 39), suggesting application of this metric can prioritise likely pathogenic variants in undiagnosed patients.
We also identify a striking enrichment of signal in patients with a phenotype of neurology and neurodevelopmental disorders, whereby their diagnostic rate increases from 60% in the whole cohort to 71%, 73% and 74% in the Dn, CCR95 and Dn_CCR95 categories respectively. This compares to the next largest phenotypic group, Ophthalmological disorders, where the corresponding values are 10%, 3% 2% and 1%.
In summary, we demonstrate the potential clinical utility of performing bespoke Dn analyses of RD patients and for incorporating CCR information into the filtering cascade to prioritise pathogenic variants. We believe such a strategy will aid the identification of pathogenic variants and decrease the time taken to make a diagnosis, thus increasing the overall diagnostic rate by allowing more samples to be analysed over the same time period.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Genomics England plc gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript